Want to join the conversation?
$BIIB 2Q15 Call: In Hemophilia, ALPROLIX revenue was $54MM and ELOCTATE revenues was $74MM. R&D expense was $491MM, or 19% of revenue. SG&A expense was $492MM or 19% of revenue. Weighted avg. diluted shares at 2Q15-end were 236MM. Revenue estimate for the rest of MS portfolio remain unchanged. OpEx as a percentage of sales remains unchanged.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.